These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

295 related articles for article (PubMed ID: 35575935)

  • 1. 5-hmC loss is another useful tool in addition to BAP1 and MTAP immunostains to distinguish diffuse malignant peritoneal mesothelioma from reactive mesothelial hyperplasia in peritoneal cytology cell-blocks and biopsies.
    Alsugair Z; Kepenekian V; Fenouil T; Glehen O; Villeneuve L; Isaac S; Hommell-Fontaine J; Benzerdjeb N
    Virchows Arch; 2022 Jul; 481(1):23-29. PubMed ID: 35575935
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Usefulness of methylthioadenosine phosphorylase and BRCA-associated protein 1 immunohistochemistry in the diagnosis of malignant mesothelioma in effusion cytology specimens.
    Berg KB; Churg AM; Cheung S; Dacic S
    Cancer Cytopathol; 2020 Feb; 128(2):126-132. PubMed ID: 31821740
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Highly expressed EZH2 in combination with BAP1 and MTAP loss, as detected by immunohistochemistry, is useful for differentiating malignant pleural mesothelioma from reactive mesothelial hyperplasia.
    Yoshimura M; Kinoshita Y; Hamasaki M; Matsumoto S; Hida T; Oda Y; Iwasaki A; Nabeshima K
    Lung Cancer; 2019 Apr; 130():187-193. PubMed ID: 30885343
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A combination of MTAP and BAP1 immunohistochemistry in pleural effusion cytology for the diagnosis of mesothelioma.
    Kinoshita Y; Hida T; Hamasaki M; Matsumoto S; Sato A; Tsujimura T; Kawahara K; Hiroshima K; Oda Y; Nabeshima K
    Cancer Cytopathol; 2018 Jan; 126(1):54-63. PubMed ID: 29053210
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The value of BRCA-1-associated protein 1 expression and cyclin-dependent kinase inhibitor 2A deletion to distinguish peritoneal malignant mesothelioma from peritoneal location of carcinoma in effusion cytology specimens.
    Althakfi W; Gazzo S; Blanchet M; Isaac S; Piaton E; Villeneuve L; Glehen O; Gilly FN; Brevet M
    Cytopathology; 2020 Jan; 31(1):5-11. PubMed ID: 31713897
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunohistochemical detection of MTAP and BAP1 protein loss for mesothelioma diagnosis: Comparison with 9p21 FISH and BAP1 immunohistochemistry.
    Hida T; Hamasaki M; Matsumoto S; Sato A; Tsujimura T; Kawahara K; Iwasaki A; Okamoto T; Oda Y; Honda H; Nabeshima K
    Lung Cancer; 2017 Feb; 104():98-105. PubMed ID: 28213009
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Utility of BAP1 Immunohistochemistry and p16 (CDKN2A) FISH in the Diagnosis of Malignant Mesothelioma in Effusion Cytology Specimens.
    Hwang HC; Sheffield BS; Rodriguez S; Thompson K; Tse CH; Gown AM; Churg A
    Am J Surg Pathol; 2016 Jan; 40(1):120-6. PubMed ID: 26448191
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genomic-based ancillary assays offer improved diagnostic yield of effusion cytology with potential challenges in malignant pleural mesothelioma.
    Kinoshita Y; Hamasaki M; Matsumoto S; Yoshimura M; Sato A; Tsujimura T; Kamei T; Kawahara K; Nabeshima K
    Pathol Int; 2020 Sep; 70(9):671-679. PubMed ID: 32542810
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The significance of BAP1 and MTAP/CDKN2A expression in well-differentiated papillary mesothelial tumour: a series of 21 cases and a review of the literature.
    Hassan A; Prabhakaran S; Pulford E; Hocking AJ; Godbolt D; Ziad F; Pandita A; Wessels A; Hussey M; Russell PA; Klebe S
    Pathology; 2024 Aug; 56(5):662-670. PubMed ID: 38789301
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hemizygous loss of NF2 detected by fluorescence in situ hybridization is useful for the diagnosis of malignant pleural mesothelioma.
    Kinoshita Y; Hamasaki M; Yoshimura M; Matsumoto S; Iwasaki A; Nabeshima K
    Mod Pathol; 2020 Feb; 33(2):235-244. PubMed ID: 31231129
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diagnostic capacity of BAP1 and MTAP in cytology from effusions and biopsy in mesothelioma.
    Lynggård LA; Panou V; Szejniuk W; Røe OD; Meristoudis C
    J Am Soc Cytopathol; 2022; 11(6):385-393. PubMed ID: 35945149
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Utility of Methylthioadenosine Phosphorylase Compared With BAP1 Immunohistochemistry, and CDKN2A and NF2 Fluorescence In Situ Hybridization in Separating Reactive Mesothelial Proliferations From Epithelioid Malignant Mesotheliomas.
    Berg KB; Dacic S; Miller C; Cheung S; Churg A
    Arch Pathol Lab Med; 2018 Dec; 142(12):1549-1553. PubMed ID: 30059257
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Loss of Methylthioadenosine Phosphorylase by Immunohistochemistry Is Common in Pulmonary Sarcomatoid Carcinoma and Sarcomatoid Mesothelioma.
    Terra S; Roden AC; Yi ES; Aubry MC; Boland JM
    Am J Clin Pathol; 2022 Jan; 157(1):33-39. PubMed ID: 34463336
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Utility of BAP1, p16, and Methylthio-Adenosine Phosphorylase Immunohistochemistry in Cytological and Histological Samples of Pleural Mesotheliomas.
    Amacher V; Bode PK; Moch H; Lenggenhager D; Vrugt B
    Acta Cytol; 2023; 67(4):444-450. PubMed ID: 36889303
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diagnostic Utility of BAP1, EZH2 and Survivin in Differentiating Pleural Epithelioid Mesothelioma and Reactive Mesothelial Hyperplasia: Immunohistochemical Study.
    Hakim SA; Abou Gabal HH
    Pathol Oncol Res; 2021; 27():600073. PubMed ID: 34257556
    [No Abstract]   [Full Text] [Related]  

  • 16. Investigation of MTAP and BAP1 staining loss and P16/CDKN2A deletion in pleural cytology specimens and its role in the diagnosis of mesothelioma.
    Şeker NS; Tekin E; Ak G; Metintaş M; Metintaş S; Dündar E
    Diagn Cytopathol; 2024 Apr; 52(4):211-216. PubMed ID: 38243885
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Challenges and limitation of MTAP immunohistochemistry in diagnosing desmoplastic mesothelioma/sarcomatoid pleural mesothelioma with desmoplastic features.
    Sa-Ngiamwibool P; Hamasaki M; Kinoshita Y; Matsumoto S; Sato A; Tsujimura T; Kasai T; Hiroshima K; Kushitani K; Takeshima Y; Kawahara K; Iwasaki A; Nabeshima K
    Ann Diagn Pathol; 2022 Oct; 60():152004. PubMed ID: 35797798
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of immunohistochemical mesothelial biomarkers in paired biopsies and effusion cytology cell blocks from pleural mesothelioma.
    Mansour MSI; Huseinzade A; Seidal T; Hejny K; Maty A; Taheri-Eilagh F; Mager U; Dejmek A; Dobra K; Brunnström H
    Cytopathology; 2023 Sep; 34(5):456-465. PubMed ID: 37337638
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diagnostic value of BRCA1-associated protein-1, glucose transporter-1 and desmin expression in the discrimination between reactive mesothelial proliferation and malignant mesothelioma in tissues and effusions.
    Önder S; Özogul E; Koksal D; Sarinc Ulasli S; Firat P; Emri S
    Cytopathology; 2019 Nov; 30(6):592-600. PubMed ID: 31165505
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Loss of BRCA1-associated protein 1 (BAP1) expression is useful in diagnostic cytopathology of malignant mesothelioma in effusions.
    Cozzi I; Oprescu FA; Rullo E; Ascoli V
    Diagn Cytopathol; 2018 Jan; 46(1):9-14. PubMed ID: 28994508
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.